[Newsmp] The Ministry of Food and Drug Safety of South Korea (MFDS, Minister Oh Yoo-kyung) said Thursday that it had approved two doses (50mg, 150mg) of the new breast cancer drug ‘Tukysa (ingredient: tucatinib)’ developed by MSD Korea.Tukysa is given in combination with capecitabine and trastuzumab

[Newsmp] Retail investors showed no interest in the pharmaceutical index's November comeback, despite its positive performance.In November, individual investors sold 6 of the 47 pharmaceutical stocks in the KOSPI market for more than KRW 10 billion, according to Newsmp's tally of net purchase amount

[Newsmp] Roche Korea's Enspryng, a treatment for neuromyelitis optica spectrum disorder (NMOSD), and GSK's Jemperli, an immune checkpoint inhibitor, will be covered by the South Korean national health insurance system.The reimbursement ceiling for existing listed products, including Cosentyx (Novart

[Newsmp] The market for high-priced drugs, such as immuno-oncology drugs, antibody-drug conjugate (ADCs), and CAR-T cell therapies, continues to grow at an accelerated pace.According to recent quarterly reports from major global pharmaceutical companies, key immunotherapy drugs recorded double-digit

[Newsmp] In the midst of stagnant growth for major pharmaceutical companies, the oncology division appears to be performing well.According to reports from major pharmaceutical companies, the oncology sector of major pharmaceutical companies experienced a boom in the third quarter, with most companie

[Newsmp] With COVID-19 finally behind us, GLP-1-based obesity and diabetes treatments are poised to become the new growth engine for big pharma.After three years of the COVID-19 pandemic, global Big Pharma is now a drag on growth.In particular, the revenues of Pfizer and Moderna, which had significa

[Newsmp] GLP-1 RA Semaglutide and the GLP-1/GIP dual agonist Tirzepatide are dominating the diabetes treatment market.The two ingredients are making waves at major diabetes conferences recently, providing productive blood sugar-lowering effects that exceed those of existing diabetes treatments of va

[Newsmp] Yuhan and Chong Kun Dang's licensed blockbusters are still holding their own.In the third quarter, Yuhan's Trajenta, the company's largest licensed product, saw a slight decrease in sales, but still recorded its best quarterly sales of any product, with sales of nearly KRW 30 billion.Biktar

[Newsmp] The number of drugs registered in the Korean version of Orange Book by the Korean Ministry of Food and Drug Safety (MFDS) in the third quarter decreased significantly.According to the MFDS information platform (https://nedrug.mfds.go.kr/), a total of 45 companies registered 79 cases in the

[Newsmp] The Ministry of Food and Drug Safety (MFDS) announced Monday that it would ease the requirement to store samples of imported rare drugs to expand treatment opportunities for patients with rare diseases and cancer.This regulation also allows for the replacement of quality inspections of radi

[Newsmp] Starting from next month, health insurance will cover Jyseleca (ingredient: filgotinib, Eisai), Nucala (ingredient: mepolizumab, GSK), and Cinqair (ingredient: reslizumab, Teva-Handok).The reimbursement ceiling for existing items, including Stelara (ingredient: ustekinumab, Janssen), Zytiga

[NESMP] The number of clinical trial approvals granted by the Korean Ministry of Food and Drug Safety (MFDS) in the third quarter increased significantly from the same period last year but decreased significantly from the previous quarter.According to the MFDS information platform (https://nedrug.mf

[Newsmp] During the last quarter, foreign ownership percentages of 8 out of 47 companies in the KOSPI pharmaceutical index increased by over 1 percentage point.In contrast, foreign ownership rates of four companies decreased by more than 1 percentage point, leaving only Dong-A ST with a foreign owne

[Newsmp] The number of drug approvals in South Korea increased slightly in the third quarter, after a sharp decline from 471 in the first quarter to 313 in the second quarter.According to the Ministry of Food and Drug Safety (MFDS) information platform (https://nedrug.mfds.go.kr/), a total of 132 co

[Newsmp] South Korea's national health insurance will cover Roche's oral Spinal Muscular Atrophy (SMA) treatment Evrysdi (ingredient: risdiplam) and its wet age-related macular degeneration (AMD) and diabetic macular edema (DME) treatment Vabysmo (ingredient: faricimab).Bayer's hemophilia A treatmen

[Newsmp]“In pursuit of a world without lung cancer deaths.“AstraZeneca showcased its lung cancer leadership at the World Conference on Lung Cancer (WCLC 2023).At the conference, the highlight session was the Plenary-Presidential Symposium, which featured over 40 abstracts, including FLAURA2, which d

[Newsmp] South Korea's Drug Reimbursement Evaluation Committee under the Health Insurance Review and Assessment Service (HIRA) has approved three drugs, including Koselugo for neurofibromatosis.During the 10th committee meeting on the 7th, HIRA has passed insurance coverage of four drugs, including

[Newsmp] After a significant drop in July, the number of Ministry of Food and Drug Safety medications has returned to its previous levels.According to the MFDS information platform (https://nedrug.mfds.go.kr/), pharmaceutical approvals for August totaled 132, surpassing the first-half monthly averag

[Newsmp] Starting from September, the South Korean pharmaceutical benefit list will include the diabetes combination drug Envlomet SR Tab. (Daewoong Pharmaceutical), the pompe disease therapy Nexviazyme (Sanofi), the heart failure treatment Verquvo (Bayer), and the growth hormone drug Ngenla (Pfizer

[Newsmp] Big pharma's oncology businesses showed a clear difference in performance.The quarterly reports focused on cancer from big pharma, compiled by Newsmp, indicate that the leading group such as companies, including MSD, Johnson & Johnson (Janssen), AstraZeneca, and Novartis, all recorded high